Abstracts tagged "Epidemiology"

Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 0991 • ACR Convergence 2024
Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations
Varinder Hans¹, Don Voaklander¹, C. Allyson Jones² and Elaine Yacyshyn², ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1353 • ACR Convergence 2024
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
Bhavik Bansal¹, Laura Gold², Katherine Wysham³, James Andrews⁴, Alexa Meara⁵, Carolyn Presley⁶, Elad Sharon⁷, Jiha Lee⁸, Jennifer Barton⁹, Una Makris¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²University of Washington, Seattle, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁶The Ohio State Medical Center, Columbus, OH, ⁷Dana Farber Cancer Institute, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹VA Portland Health Care System/OHSU, Portland, OR, ¹⁰UT Southwestern Medical Center and Dallas VA, Dallas, TX, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Amadeia Rector¹, Emily Liu², Miranda Cantu³, Eliza Chakravarty⁴, Maurice Druzin⁵, Gary Shaw⁶, Michael Weisman⁷, Monique Hedderson² and Julia Simard⁸, ¹Stanford University, San Francisco, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Patient partner, Portage, MI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, ⁷Stanford University, Los Angeles, CA, ⁸Stanford School of Medicine, Stanford, CA
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 2489 • ACR Convergence 2024
Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
Naomi Patel¹, Ana Fernandes¹, Andrew King¹, Shruthi Srivatsan¹, Colebrook Johnson¹, Zachary Williams¹, Madison Negron¹, Caleb Bolden¹, Miao Lin¹, Bohang Jiang¹, Sam Oh², Darcy Trimpe², Sushmitha Inguva² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Amgen Inc., Thousand Oaks, CA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Avacopan is approved in the US for use in adults with severe active GPA or MPA alongside background immunosuppression. Efficacy and safety data on…
Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
Abstract Number: 0133 • ACR Convergence 2024
The Association Between Gout and Gallstone Disease: US General Population Analysis
Chio Yokose¹, Bohang Jiang², Natalie McCormick², Sharan Rai² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout is associated with kidney stones, but its association with gallstone disease is not known. Gout and gallstone disease have several shared risk factors…
Abstract Number: 0162 • ACR Convergence 2024
Statewide Burden of Low Back Pain in the United States and Its Trend from 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2022
Eva Kalra¹, Rafael Sanchez-Dopazo,², Lovekumar Vala³, Vani Sojitra⁴, Riya Dhadhal⁵, Praveena Suppala⁶, Mohammed A. S. Aramin⁷, Krishna Sajeev⁸ and Hardik Desai⁹, ¹Trident Medical Cente, Charleston, SC, ²Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ³Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁴Pandit Deendayal Upadhyay Medical College, Rajkot,, Rajkot, Gujarat, India, ⁵SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁶SVS Medical College, Yenugonda, Mahbubnagar, Telangana, India,, Telangana, Telangana, India, ⁷Alquds university,Jerusalem,Palestine, P144, Gaza, Palestinian Territories, ⁸Government medical college, Kannur, kerala , India, 670503, Kunnur, Kerala, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Low back pain (LBP) ranks as the fourth leading cause of disability in the United States, significantly impacting the quality of life and work…
Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0719 • ACR Convergence 2024
Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
Joanna El Hajj¹, Jennifer Waller¹, Yagni Patel¹, Wendy Bollag¹, Stephanie Baer² and Rachel Elam³, ¹Augusta University, Augusta, GA, ²VA Augusta Healthcare System, Augusta, GA, ³Augusta University, Evans, GA
Background/Purpose: End-stage renal disease (ESRD) secondary to vasculitis is linked to a higher risk of vertebral fractures compared to other causes of ESRD. It remains…
Abstract Number: 0993 • ACR Convergence 2024
Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis
Muhammad Naveed¹, Rabia Iqbal¹, Kishan Patel², Ahila Ali¹, Simran Bhimani³, Bazil Azeem⁴, Yash Deshpande³, Muhammad Omer Rehan¹, Faizan Ahmed⁵, Hussain Haider Shah¹ and Nouman Shafique⁶, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA, ⁴Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁵Ameer-ud-Din Medical College, Lahore, Pakistan, ⁶AdventHealth Orlando, Orlando, FL
Background/Purpose: Pulmonary complications in rheumatoid arthritis (RA) are an important cause of mortality among older adults. This study analyzes trends and demographic disparities in mortality…
Abstract Number: 1099 • ACR Convergence 2024
Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women
Sharan Rai¹, Hyon K. Choi², Chio Yokose¹ and Natalie McCormick¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate levels in physiologic studies, and a Mendelian Randomization…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].